NYSEAMERICAN:IMUC - ImmunoCellular Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.0248 -0.01 (-17.33 %)
(As of 02/20/2019 04:00 PM ET)
Previous Close$0.03
Today's Range$0.0246 - $0.0299
52-Week Range$0.0140 - $0.36
Volume272,177 shs
Average Volume254,709 shs
Market Capitalization$1.04 million
P/E RatioN/A
Dividend YieldN/A
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its products include ICT-107, a dendritic cell (DC) immunotherapy for the treatment of diagnosed glioblastoma multiforme (GBM); ICT-140, a DC-based immunotherapy targets tumor associated antigens on ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs to treat recurrent GBM and other solid tumor cancers. The company is developing Steam-to-T-Cell immunotherapies for the treatment of cancer. It has license agreements with California Institute of Technology and The Johns Hopkins University. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Westlake Village, California.

Receive IMUC News and Ratings via Email

Sign-up to receive the latest news and ratings for IMUC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesN/A



Market Cap$1.04 million
OptionableNot Optionable

ImmunoCellular Therapeutics (NYSEAMERICAN:IMUC) Frequently Asked Questions

What is ImmunoCellular Therapeutics' stock symbol?

ImmunoCellular Therapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IMUC."

How were ImmunoCellular Therapeutics' earnings last quarter?

ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) released its quarterly earnings results on Monday, August, 13th. The biotechnology company reported ($0.01) earnings per share for the quarter. View ImmunoCellular Therapeutics' Earnings History.

Has ImmunoCellular Therapeutics been receiving favorable news coverage?

News stories about IMUC stock have trended neutral recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ImmunoCellular Therapeutics earned a media sentiment score of 0.3 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the near future.

Who are some of ImmunoCellular Therapeutics' key competitors?

Who are ImmunoCellular Therapeutics' key executives?

ImmunoCellular Therapeutics' management team includes the folowing people:
  • Mr. Gary S. Titus, Chairman & Corp. Sec. (Age 58)
  • Dr. Anthony J. Gringeri, CEO, Pres & Director (Age 65)
  • Dr. John S. Yu, Founder & Director (Age 54)
  • Mr. David E. Fractor, Chief Financial Officer (Age 58)
  • Dr. Steven J. Swanson, Sr. VP of Research (Age 62)

How do I buy shares of ImmunoCellular Therapeutics?

Shares of IMUC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ImmunoCellular Therapeutics' stock price today?

One share of IMUC stock can currently be purchased for approximately $0.0248.

How big of a company is ImmunoCellular Therapeutics?

ImmunoCellular Therapeutics has a market capitalization of $1.04 million. ImmunoCellular Therapeutics employs 3 workers across the globe.

What is ImmunoCellular Therapeutics' official website?

The official website for ImmunoCellular Therapeutics is http://imuc.com/.

How can I contact ImmunoCellular Therapeutics?

ImmunoCellular Therapeutics' mailing address is 30721 Russell Ranch Rd Ste 140, WESTLAKE VILLAGE, CA 91362-7383, United States. The biotechnology company can be reached via phone at +1-818-2642300.

MarketBeat Community Rating for ImmunoCellular Therapeutics (NYSEAMERICAN IMUC)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  208 (Vote Outperform)
Underperform Votes:  205 (Vote Underperform)
Total Votes:  413
MarketBeat's community ratings are surveys of what our community members think about ImmunoCellular Therapeutics and other stocks. Vote "Outperform" if you believe IMUC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMUC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel